Valuation: Ovid Therapeutics Inc.

Market Cap 43Cr 38Cr 36Cr 33Cr 61Cr 4.19TCr 62Cr 421.79Cr 164.79Cr 2.06TCr 163.25Cr 159.73Cr 7.12TCr P/E 2026 *
-4.82x
P/E 2027 * -4.37x
Enterprise Value 43Cr 38Cr 36Cr 33Cr 61Cr 4.19TCr 62Cr 421.79Cr 164.79Cr 2.06TCr 163.25Cr 159.73Cr 7.12TCr EV / Sales 2026 *
4,045x
EV / Sales 2027 * 2,609x
Free-Float
92.96%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day+2.79%
1 week+5.42%
Current month-9.67%
1 month-10.66%
3 months-9.67%
6 months+34.25%
Current year+49.08%
1 week 2.29
Extreme 2.29
2.52
1 month 2.29
Extreme 2.29
2.84
Current year 1.36
Extreme 1.36
3.1
1 year 0.48
Extreme 0.475
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.2
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 01/01/2026
Director of Finance/CFO 59 06/07/2026
Chief Tech/Sci/R&D Officer 60 02/12/2025
Director TitleAgeSince
Chairman 72 01/04/2014
Director/Board Member 81 23/11/2015
Director/Board Member 61 14/06/2017
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Free

Chief Financial Officer

50,000 0.0268%
06/07/26 Other

Chief Financial Officer

4,50,625 0.2414%
15/06/26 Free

Director

1,30,000 0.0697%
Change 5-day change 1-year change 3-year change Capi.($)
+2.79%+5.42%+360.66%-30.07% 43Cr
-1.34%+5.20%+54.90%+69.00% 5.73TCr
-1.92%+6.03%+40.64%+80.66% 5.5TCr
-0.21%-0.32%+4.84%+422.92% 2.32TCr
+2.48%-0.62%-18.80%-12.77% 2.26TCr
-1.13%+1.05%+20.81%-7.73% 2.05TCr
+1.04%+2.95%+26.98%-29.31% 1.76TCr
-0.10%+1.88%+34.42%+545.91% 1.57TCr
-1.30%-5.02%+170.77%+310.94% 1.45TCr
+1.55%+1.66%+27.17%+188.01% 1.39TCr
Average +0.18%+0.70%+72.24%+153.76% 2.41TCr
Weighted average by Cap. -0.58%+2.08%+39.54%+136.70%

Financials

2026 *2027 *
Net sales 1L 94.42T 87.81T 80.57T 2L 1.04Cr 2L 10.43L 4L 50.9L 4L 4L 1.76Cr 2L 1L 1L 1L 2L 1.61Cr 2L 16.17L 6L 78.91L 6L 6L 2.73Cr
Net income -7.71Cr -6.77Cr -6.3Cr -5.78Cr -11Cr -742.69Cr -11Cr -75Cr -29Cr -365.13Cr -29Cr -28Cr -1.26TCr -8.98Cr -7.89Cr -7.34Cr -6.73Cr -13Cr -865.17Cr -13Cr -87Cr -34Cr -425.35Cr -34Cr -33Cr -1.47TCr
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
27/26/27 $2.430 +4.30% 1,63,100
24/26/24 $2.330 -2.92% 9,84,979
23/26/23 $2.400 +0.84% 47,28,431
22/26/22 $2.380 -1.24% 10,86,787
21/26/21 $2.410 +4.56% 17,79,649
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.330USD
Average target price
5.471USD
Spread / Average Target
+134.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock